$ABT

Abbott settlement directs more than $9.3 million to New York over baby formula claims

Abbott Laboratories will pay $384 million to resolve claims it sold potentially contaminated baby formula through Medicaid and WIC programs. New York will receive $9.3 million, with $5.3 million going directly to the state. The settlement follows a 2025 lawsuit alleging safety standard violations and misled inspections.

Original reporting
Published Sep 18, 2026, 2:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 2:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Abbott settlement directs more than $9.3 million to New York over baby formula claims — source image
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The settlement resolves the case, imposing a $384M payment and may affect Abbott's short-term earnings and stock perception.

02

Market read

Legal settlement introduces a material liability for Abbott, likely prompting short-term price adjustment.

03

What to watch

Potential for improved compliance and future product safety could mitigate risk.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott faced a 2025 lawsuit alleging safety lapses in formula production for Medicaid and WIC programs.

Company-level read

Ticker impact

$ABTBearishMedium confidence
Context

Abbott Laboratories agreed to pay $384M settlement, including $9.3M to New York, a new legal liability.

Expected impact

Expect modest downside pressure over the next few days.

Evidence & confidence

Settlement size is material; market may price in liability, but impact likely limited to short-term sentiment.

Market effects

May raise scrutiny on infant nutrition and consumer health product manufacturers.

New York Medicaid program recovers funds, limited broader regional effect.

Highlights regulatory risk for global baby formula producers.

Counterpoint

Settlement may be viewed as a one-time charge; long-term fundamentals remain strong.

Key entities

  • Abbott Laboratories

    Infant formula manufacturer paying settlement.

  • New York Attorney General Letitia James

    Announced the settlement and fund allocation.

Related articles

$ABTMedAI 8/10

Attorney General James Secures Over $9 Million for New York from Abbott Laboratories for Manufacturing Potentially Unsafe Baby Formula

New York Attorney General Letitia James announced a settlement with Abbott Laboratories, where the company will pay over $384 million for alleged safety violations in its baby formula products. Abbott is accused of failing to maintain safety standards from 2018 to 2022, leading to potential contamination and misuse of Medicaid and WIC funds. New York will receive over $9.3 million from the settlement.

$ABTMedAI 8/10

Abbott Must Pay $384M for 2022 Contaminated Baby Formula: Who Gets the Payout

Abbott Laboratories agreed to pay $385M to settle allegations of selling contaminated infant formula to government programs, contributing to the 2022 formula crisis. The settlement resolves False Claims Act allegations but does not establish a consumer claims process. The Justice Department emphasized the importance of adhering to health and safety standards for infant formula.

$ABTHighAI 9/10

Abbott Laboratories agrees to pay more than $384 million to settle infant formula allegations

Abbott Laboratories agreed to pay over $384 million to settle allegations of submitting false claims for infant formula and nutritional products. The settlement includes $348.7 million to the federal government and $35.5 million to states, resolving claims involving products made between 2018 and 2022 at facilities in Michigan and Arizona. Authorities alleged Abbott failed to meet safety and regulatory requirements, leading to potential contamination risks. The settlement does not admit liabilit

$ABTMedAI 8/10

Abbott to Pay $385 Million to End Claims Over Infant Formula

Abbott Laboratories will pay $385 million to settle U.S. claims over alleged poor manufacturing practices at its infant formula facilities, including a plant in Michigan linked to a 2022 recall and nationwide shortage. The settlement resolves allegations of unsanitary conditions and contamination risks, though Abbott denies liability. The company will pay $348.7 million to the U.S. and $36.3 million to states, with whistleblowers receiving $69 million. This follows a separate $670 million settle

$ABTMedAI 8/10

Oregon gets $977k from settlement over baby formula safety allegations

Abbott Laboratories will pay $384M to settle allegations of unsafe manufacturing conditions for baby formula and nutritional products. Oregon receives $977,558. The settlement covers violations from 2018-2022, with Abbott paying $348.7M to the federal government and $35.5M to 39 states for Medicaid claims. The affected products were sold through government assistance programs like WIC and Medicaid.